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vasoconstrictive effect. No adverse events related to the 
study medications were observed. Good topical bioavail-
ability of both DM formulations was detected by chroma-
metric measurement and clinical assessment. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Topical corticosteroids represent the treatment of 
choice for numerous different inflammatory skin diseas-
es, in particular atopic eczema. The great variety of topi-
cal corticosteroid formulations currently available does 
not always allow dermatologists and general practition-
ers to easily select the best suitable corticosteroid in a giv-
en context. The desired anti-inflammatory effects of cor-
ticosteroids with conventional formulations unfortu-
nately correlate strictly with the undesired effects, e.g. 
skin atrophy  [1] . The potency of the corticosteroids has 
been classified by Niedner  [2] . Accordingly, class I com-
prises mild corticosteroids, class II medium potent ones, 
class III potent ones and class IV the strongest congeners. 
The classification reflects their relative efficacy. The va-
soconstriction assay (blanching test), first described by 
McKenzie and Stoughton  [3] in 1962, is a test known to 
be suitable to determine the activity of topically applied 
corticosteroids  [3–5] . Vasoconstriction is a pharmacolog-
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 Abstract 
 Introduction: We report on a double-blind, vehicle-con-
trolled, single-center confirmatory study with random as-
signment. The purpose of the study was to investigate the 
topical bioavailability of different topical corticosteroid for-
mulations in healthy human beings focussing on desox-
imetasone (DM).  Materials and Methods: Two DM 0.25% 
formulations [ointment (DM-o) and fatty ointment (DM-fo, 
water-free); class III corticosteroids], the corresponding ac-
tive ingredient-free vehicles and three comparators of differ-
ent strength [clobetasol propionate 0.05% (CP 0.05%), fatty 
ointment, class IV; hydrocortisone (HC) 1%, fatty ointment, 
class I, and betamethasone (BM) 0.05%, fatty ointment, class 
III] were tested using the vasoconstriction assay. The degree 
of vasoconstriction (blanching) in the treatment field was 
compared to the one found in untreated control fields using 
chromametric measurements and clinical assessment.  Re-
sults/Conclusion: DM-o 0.25%, DM-fo 0.25% and BM 0.05% 
showed similar vasoconstrictive potential, i.e., clear blanch-
ing. In fact, both DM preparations were proven to be non-
inferior to BM 0.05%, while CP 0.05% was found a little less 
active. HC 1.0% and the DM vehicles showed no clear-cut 
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ical activity, which correlates well with clinical efficacy. 
The intensity of skin blanching after a single topical ap-
plication under occlusion as a sign of pharmacological 
activity corresponds generally to the clinical efficacy af-
ter repeated application without occlusion. The test de-
scribes the time- and dose-dependent blanching of the 
skin after the single application of a corticosteroid with 
respect to the anti-inflammatory activity and thus indi-
rectly allows to assess topical bioavailability  [6] . 
 Desoximetasone (DM), introduced into clinical ther-
apy more than 25 years ago  [7] , has been known to be an 
effective topical therapeutic option for the treatment of 
atopic dermatitis  [8] and other types of eczema  [9, 10] . Yet 
there is still a need for experimental data allowing a com-
parison of different DM formulations and other topical 
corticosteroid formulations of different potency. In the 
present study, different corticosteroid formulations and 
their vehicles were tested using the vasoconstriction as-
say in particular to obtain information about the topical 
bioavailability of the active pharmaceutical ingredients.
 Materials and Methods 
 Study Design 
 This clinical trial was conducted conforming to EC-GCP (Eu-
ropean Community Good Clinical Practice) standards as a sin-
gle-center, vehicle-controlled, double-blind study with random 
assignment. The final study protocol was approved by the rele-
vant Ethics Committee before the start of the study. Male and 
female eligible volunteers, older than 18 years with healthy skin 
demonstrating vasoconstriction to topical corticosteroids, i.e. ‘re-
sponders’, were included after having given their informed con-
sent. 
 Two DM 0.25% test preparations [Topisolon  ointment (DM-
o) and Topisolon  fatty ointment (DM-fo, water-free), each class 
III corticosteroids], the corresponding active ingredient-free ve-
hicles and three comparators of different strength [Karison  (clo-
betasol-17-propionate 0.05% [CP 0.05%], class IV), Sanatison  
Mono 1% (hydrocortisone 1.0% [HC 1.0%], class I) and Diprosis  
(betamethasone dipropionate 0.064% = betamethasone 0.05% 
[BM 0.05%], water-free, class III)] were tested in a nonocclusive 
manner. The chemical name of DM is pregna-1,4-diene-3,20-di-
one-9-fluoro-11,21-dihydroxy-16-methyl-(11  , 16  ). Its struc-
ture is depicted in  figure 1 . 
 The test fields were compared intraindividually. Altogether 9 
test fields were evaluated. Four test fields were located on one vo-
lar forearm and 5 on the other. Two untreated test fields, 1 on each 
arm, served as internal controls. A single application under occlu-
sion of each formulation was performed for 6 h. Chromametric 
measurements and clinical assessments were performed at base-
line (prior to application) and 1, 2, 4, 6 and 18 h after application. 
One single nonocclusive application of each formulation over 6 h 
 8 15 min was performed. A self-adhesive electrocardiogram 
(ECG) ring (inside diameter 16 mm) was centered and attached to 
each of the test fields (allowing at least 2 cm between test fields). 
A Teflon ring (inside diameter 16 mm, height approximately
3 mm) was attached to the inner opening of the electrocardio-
gram ring. Approximately 50   l formulation were applied to each 
test field. The test fields were covered with a single layer of gauze 
being fixed on the edges with an adhesive bandage to prevent con-
tamination. The individual test fields were treated using a 1-ml 
syringe in accordance with the permutation in the randomization 
list. A total dose of approximately 50   l of DM-o and 50   l of DM-
fo correspond together to 0.125 mg DM each; 50   l of CP 0.05% 
correspond to 0.025 mg CP; 50   l of HC 1.0% correspond to 0.5 
mg HC, and 50   l of BM 0.05% correspond to 0.025 mg BM di-
propionate. All subjects received the same treatments. There was 
no interindividual subdivision into treatment groups. The test 
fields with the active formulations and the corresponding vehicles 
were arranged contralaterally. The three comparators were ran-
domly assigned to 1 of the 3 remaining test fields. The investiga-
tional products were blinded in neutral tubes. 
 Relevant previous treatments applied within 12 weeks before 
the study were documented. The following concomitant treat-
ments were not permitted during this study: any vasoactive (con-
strictor or dilator) medication that modulates blood flow includ-
ing nitroglycerin, antihypertensives, antihistamines, nonsteroi-
dal anti-inflammatory drugs, aspirin and cough/cold products 
containing antihistamines and/or either phenylpropanolamine 
or phentolamine and glucocorticoids. 
 Study Population 
 Thirty healthy subjects were enrolled in the study, random-
ized and treated with the study medications. All subjects finished 
the study as planned. All included volunteers received one appli-
cation of each formulation over 6 h  8 15 min and one addition-
al application with BM 0.05% during the screening examina-
tion over 6 h  8 15 min in order to determine whether they
were blanching responders. Ten male and 20 female subjects 
formed the study population. Their age ranged from 18 to 69 years 
(mean = 35.8, SD = 13.0). Four subjects were using concomitant 
medication for contraception. Two other volunteers once took 
paracetamol for the treatment of headache during the study. 
 Chromametry 
 Skin color measurements were made according to the method 
of Queille-Roussel et al.  [11] with a Chromameter CR 300 (Mi-
nolta, Ahrensburg, Germany). Values were measured in accor-
dance with the L * a * b * system. The a * value (redness value) is a 
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 Fig. 1. Structure of DM. 
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well-accepted parameter in the context of vasoconstrictor assays. 
Measurements were performed by placing the detector without 
additional pressure on the test fields. Three measurements were 
taken at each field at a given time point. 
 Clinical Assessment 
 The degree of vasoconstriction was clinically assessed at the 
treatment field compared to the untreated control field on the 
same forearm ( table 1 ). This clinical assessment of the test fields 
was performed by an independent observer. Bathing, showering, 
sauna, natural sun bathing or solarium was not allowed during 
the study. Extensive exercising especially with the arms had to be 
avoided during the study. The use of skin care products (e.g. 
creams, emollients) on both forearms 24 h prior to and through-
out the study was prohibited, as was any caffeine intake during 
the study. 
 Data Handling 
 Double data entry was performed. The first and second data 
entry was carried out by two different persons (data entry opera-
tors). Vasoconstriction properties were determined by evaluation 
of the degree of blanching in the test fields. The primary efficacy 
variable was the a * value (redness value) measured by chromam-
etry. Clinical assessment scores for the degree of vasoconstriction 
were recorded as a secondary variable. 
 Statistical Analysis 
 The statistical evaluation in this confirmatory trial was per-
formed using the software program SAS. The study aim was to 
prove the efficacy of the active study preparations (DM-o and 
DM-fo) compared to the corresponding vehicles and to compare 
them to other corticosteroids. Vasoconstriction (blanching), ex-
pressed as a * values, was used as a measure for efficacy. The a * 
values for the assessment point 1 h after treatment were used. 
Since two active study preparations (DM-o and DM-fo) were test-
ed versus the corresponding vehicles, an alpha adjustment ac-
cording to Bonferroni was performed  [12] . The following hierar-
chical approach was performed for both active study preparations 
(DM-o and DM-fo) and the corresponding active ingredient-free 
vehicles.
 (1) Comparison of blanching induced by the active study prep-
arations (DM-o and DM-fo) with blanching due to the corre-
sponding vehicles. The difference between the treatments was es-
timated with a 2-sided 97.5% confidence interval and compared 
to 0.
 (2) Comparison of blanching induced by the active study prep-
arations (DM-o and DM-fo) with a comparator of lower strength. 
The difference between the treatments (comparator minus active 
study preparation) was estimated with a 2-sided 95% confidence 
interval corresponding to an upper 1-sided 97.5% confidence in-
terval. The upper 97.5% confidence interval was discussed with 
reference to 25% of the mean of the data related to the com-
parator.
 (3/4) Comparisons with comparators of similar and higher 
strength, respectively, as outlined in 2. Step 2 was only to be per-
formed if the comparison of the active study preparation and the 
vehicle in step 1 revealed superiority of the active study prepara-
tion. In analogy, steps 3 and 4 were performed if steps 2 and 3 
revealed noninferiority of the active study preparation. This or-
dered test procedure kept the overall significance level of 5%.
 Sums of clinical assessment scores were evaluated descrip-
tively.
 Results 
 Analyses of the Primary Activity Parameter – 
Blanching 
 The efficacy analysis was primarily performed based 
on chromametric data measured 1 h after the 6-hour ap-
plication period. The baseline-corrected, untreated con-
trol site-corrected a * values reflect the degree of blanch-
ing. Clear blanching was observed in the fields treated 
with DM-o, DM-fo and the active comparators BM 0.05% 
and CP 0.05%. The mean degree of blanching was similar 
for DM-o, DM-fo, BM 0.05% and CP 0.05%. Since the 
lower 97.5% confidence limits of DM-o and DM-fo were 
greater than 0, it can be concluded that both preparations 
were active with respect to blanching. The lower 97.5% 
confidence limits of BM 0.05% and CP 0.05% were also 
greater than 0. In the fields treated with the comparator 
HC 1.0% only slight blanching was observed. The lower 
97.5% confidence limit for HC 1.0% was –0.07. Therefore, 
it could not be verified that HC 1.0% is significantly ac-
tive with respect to blanching. 
 For the DM-o and DM-fo vehicles, a slight blanching 
was observed. The mean degree of blanching was compa-
rable for the DM-o vehicle and the DM-fo vehicle. The 
lower 97.5% confidence limits were 0.21 and 0.06 for the 
DM-o and DM-fo vehicles, respectively. The comparison 
of DM-o with its vehicle showed no overlap between the 
corresponding 97.5% confidence intervals. Since the low-
er 97.5% confidence limit of 1.62 was greater than 0, it can 
be concluded that DM-o was more effective than its ve-
hicle.
 In order to judge whether DM-o was noninferior to 
HC 1.0%, the difference of mean blanching after treat-
ment with HC 1.0% minus mean blanching after treat-
ment with DM-o was calculated. It could be confirmed 
that DM-o was noninferior to HC 1.0% when considering 
a 25% margin. In order to judge whether DM-o was non-
Table 1. Scores to measure the degree of vasoconstriction of a 
treatment field compared to the untreated control field
0 No vasoconstriction
1 Mild vasoconstriction
2 Moderate vasoconstriction
3 Intense vasoconstriction
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inferior to BM 0.05%, the difference of mean blanching 
after treatment with BM 0.05% minus mean blanching 
after treatment with DM-o was calculated. The upper 
95% confidence limit of the difference between both 
treatments (0.75) should be below 25% of the mean for 
BM 0.05% (25% of 3.26 is 0.82). DM-o was noninferior to 
BM 0.05%. The actual upper 95% confidence limit was 
23% of the comparator’s mean effect. In order to judge 
whether DM-o was found noninferior to CP 0.05%, the 
difference of mean blanching after treatment with CP 
0.05% minus mean blanching after treatment with DM-o 
was calculated. It could be confirmed that DM-o was 
noninferior to CP 0.05% when considering a 25% margin. 
The actual upper 95% confidence limit was 8% of the 
comparator’s mean effect. 
 The comparison of DM-fo with its vehicle showed no 
overlap between the corresponding 97.5% confidence in-
tervals. It could be concluded that DM-fo was more active 
than its vehicle. In order to judge whether DM-fo was 
noninferior to HC 1.0%, the difference of mean blanch-
ing after treatment with HC 1.0% minus mean blanching 
after treatment with DM-fo was calculated. The upper 
95% confidence limit of the difference between both 
treatments (–2.45) should be below 25% of the HC 1.0% 
mean (25% of 0.37 is 0.09). Since –2.45 is below 0.09, it can 
be confirmed that DM-fo was noninferior to HC 1.0% 
when considering a 25% margin. In order to judge wheth-
er DM-fo was noninferior to BM 0.05%, the difference of 
mean blanching after treatment with BM 0.05% minus 
mean blanching after treatment with DM-fo was calcu-
lated. The upper 95% confidence limit of the difference 
between both treatments (0.28) should be below 25% of 
the BM 0.05% mean (25% of 3.26 is 0.82). It could be con-
firmed that DM-fo was noninferior to BM 0.05% when 
considering a 25% margin. The actual upper 95% confi-
dence limit was 9% of the comparator’s mean effect. In 
order to judge whether DM-fo was noninferior to CP 
0.05%, the difference of mean blanching after treatment 
with CP 0.05% minus mean blanching after treatment 
with DM-fo was calculated. The upper 95% confidence 
limit of the difference between both treatments (–0.22) 
should be below 25% of the CP 0.05% mean (25% of 2.73 
is 0.68). Since –0.22 is below 0.68, it can be confirmed that 
DM-fo was noninferior to CP 0.05% when considering a 
25% margin ( table 2 ;  fig. 2 ).
 Analyses of Secondary Efficacy Variables –
Clinical Assessment of Vasoconstriction 
 For the treatments with DM-o, DM-fo, BM 0.05% and 
CP 0.05% the score sums were maximal during the first 
6 h after the end of the treatment period and ranged be-
tween 58 and 60 after treatment with DM-o, DM-fo and 
BM 0.05% and between 48 and 51 after treatment with CP 
0.05% at the different assessment points ( table 3 ). A 
marked decrease in the score sum was recorded 18 h after 
the end of treatment (DM-o, score sum: 15; DM-fo, score 
sum: 14; BM 0.05%, score sum: 19; CP 0.05%, score sum: 
16).
Table 2. Descriptive statistics of the clinical assessment
TP, h n Median Sum Score 
0 1 2 3
DM-o-V 1 30 0 15 17 11 2 0
2 30 0 16 17 10 3 0
4 30 0 16 19 6 5 0
6 30 0 11 20 9 1 0
18 30 0 2 28 2 0 0
DM-o 1 30 2 59 1 4 20 5
2 30 2 60 1 3 21 5
4 30 2 60 1 3 21 5
6 30 2 58 1 3 23 3
18 30 0 15 16 13 1 0
DM-fo-V 1 30 0 10 20 10 0 0
2 30 0 9 21 9 0 0
4 30 0 6 25 4 1 0
6 30 0 5 26 3 1 0
18 30 0 1 29 1 0 0
DM-fo 1 30 2 60 0 4 22 4
2 30 2 59 1 3 22 4
4 30 2 60 0 3 24 3
6 30 2 58 0 3 26 1
18 30 0 14 16 14 0 0
HC 1.0% 1 30 0 9 21 9 0 0
2 30 0 7 23 7 0 0
4 30 0 5 25 5 0 0
6 30 0 2 28 2 0 0
18 30 0 3 27 3 0 0
BM 0.05% 1 30 2 58 0 5 22 3
2 30 2 60 0 4 22 4
4 30 2 60 0 4 22 4
6 30 2 60 0 2 26 2
18 30 1 19 11 19 0 0
CP 0.05% 1 30 2 48 4 6 18 2
2 30 2 50 3 6 19 2
4 30 2 51 2 7 19 2
6 30 2 51 0 10 19 1
18 30 0.5 16 15 14 1 0
DM-o-V = DM-o vehicle; DM-fo-V = DM-fo vehicle; TP = 
time point.
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 For the DM-o vehicle, the score sums were maximal 
during the first 4 h after the end of treatment and ranged 
between 15 and 16. A decrease in the score sum to 11 was 
observed at the 6-hour assessment point, and to a score 
sum of 2 at the 18-hour assessment point. 
 After treatment with the DM-fo vehicle and after treat-
ment with HC 1.0% the highest score sum was assessed
1 h after the end of treatment (score sums 10 and 9, re-
spectively).
 As in the analysis of the chromametric data, the de-
scription of the clinical assessment is focussed on the data 
assessed 1 h after the end of treatment. In the fields treat-
ed with the DM-o vehicle, some vasoconstriction was ob-
served in 13 subjects, leading to a score sum of 15. In 11 
cases, mild vasoconstriction (score 1) and in 2 cases mod-
erate vasoconstriction (score 2) was observed. In the 
fields treated with DM-o, vasoconstriction was found in 
29 subjects (score sum: 59). Mild vasoconstriction was 
found in 4 cases, moderate vasoconstriction in 20 cases 
and intense vasoconstriction (score 3) in 5 cases. In the 
fields treated with the DM-fo vehicle, mild vasoconstric-
tion was observed in 10 subjects, leading to a score sum 
of 10. In the fields treated with DM-fo, some vasocon-
striction was noted in all 30 subjects (score sum: 60). Mild 
vasoconstriction was observed in 4 cases, moderate vaso-
constriction in 22 cases and intense vasoconstriction in 
4 cases. 
DM-o-V DM-o DM-fo-V DM-fo HC 1.0% BM 0.05% CP 0.05%
1 h 2 h 4 h 6 h 18 h
0
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 Fig. 2. Score sums of the clinical assess-
ment of vasoconstriction. DM-o-V =
DM-o vehicle; DM-fo-V = DM-fo vehicle. 
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 Fig. 3. Mean baseline-corrected, untreated 
control site-corrected a * values. DM-o-V = 
DM-o vehicle; DM-fo-V = DM-fo vehicle. 
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 In the fields treated with HC 1.0%, mild vasoconstric-
tion was observed in 9 subjects, leading to a score sum
of 9. 
 In the fields treated with BM 0.05%, some vasocon-
striction was found in all 30 subjects (score sum: 58). Mild 
vasoconstriction was noted in 5 cases, moderate vasocon-
striction in 22 cases and intense vasoconstriction in 3 
cases.
 In the fields treated with CP 0.05%, some vasocon-
striction was found in 26 subjects, leading to a score sum 
of 48. In 6 cases, mild vasoconstriction, in 18 cases mod-
erate and in 2 cases intense vasoconstriction was ob-
served ( table 2 ;  fig. 2 ).
 Activity Conclusions 
 Under the conditions in this vasoconstrictor assay 
DM-o and DM-fo showed clear blanching. Accordingly, 
topical bioavailability of DM was shown for both Topiso-
lon formulations. In contrast, both corresponding vehi-
cles showed only slight blanching. The comparisons be-
tween the Topisolon formulations and the corresponding 
vehicles showed that the active formulations were obvi-
ously more active. The active comparators with similar 
(BM 0.05%) or higher strength (CP 0.05%) showed simi-
lar blanching effects as the DM formulations. Less of a 
blanching effect was noted for the comparator with lower 
strength (HC 1.0%).
 The chromametric measurements demonstrated clear 
reduction in skin redness for DM-o, DM-fo, BM 0.05% 
and CP 0.05%. The mean a * values were similar for these 
formulations. In the fields treated with HC 1.0%, only
a slight reduction in skin redness was observed (mean
a * value: 0.37). In the fields treated with the DM-o ve-
hicle and the DM-fo vehicle, the mean a * values were 
comparable amounting to 0.61 and 0.41, respectively 
( tables 1–3 ). 
 The blanching effects of DM-o, DM-fo, BM 0.05% and 
CP 0.05% were confirmed by the lower 97.5% confidence 
limits of the mean a * values being greater than 0. The cor-
responding 97.5% confidence intervals for the DM for-
mulations and the comparators of similar and higher 
strength (BM 0.05% and CP 0.05%) showed an overlap in 
every case. No overlap was seen between the DM formu-
lations and the comparator of lower strength (HC 1.0%) 
and between the DM formulations and their correspond-
ing vehicles. 
 Furthermore, both DM-o and DM-fo were noninferi-
or to each of the comparators when considering a 25% 
margin.
 Comparing the data 1 h after the end of treatment, the 
results of the clinical assessment reflect the chromamet-
ric data. DM-o, DM-fo, BM 0.05% and CP 0.05% had a 
clearly greater effect than both vehicles and HC 1.0%. 
 The vehicles and HC 1.0% had no clear-cut vasocon-
strictive effect. DM-o, DM-fo and BM 0.05% showed a 
similar vasoconstrictive potential. CP 0.05% was found a 
little less active. No serious adverse events were reported 
during the entire study ( table 3 ;  fig. 3 ).
Table 3. Descriptive statistics for baseline-corrected, untreated 
control site-corrected a* values
TP
h
n Mean SD Min Max Lower
95% CL
Upper
95% CL
DM-o-V 1 30 0.61 0.93 –0.98 2.71 0.27 0.96
2 30 0.50 0.97 –0.92 3.37 0.14 0.87
4 30 0.41 1.16 –1.67 2.52 –0.03 0.84
6 30 0.24 1.13 –1.33 3.15 –0.18 0.67
18 30 –0.16 0.84 –2.60 1.68 –0.47 0.15
DM-o 1 30 2.93 1.46 –1.26 5.38 2.39 3.47
2 30 2.93 1.38 –0.15 6.14 2.41 3.44
4 30 2.76 1.14 –0.32 4.61 2.34 3.19
6 30 3.00 1.32 0.88 6.12 2.51 3.49
18 30 0.61 1.13 –1.94 2.65 0.19 1.04
DM-fo-V 1 30 0.41 0.81 –1.47 2.56 0.11 0.72
2 30 0.14 0.92 –1.72 2.45 –0.20 0.49
4 30 –0.32 0.90 –1.90 2.55 –0.65 0.02
6 30 –0.22 1.01 –1.84 2.30 –0.60 0.16
18 30 –0.18 0.78 –1.96 1.10 –0.47 0.11
DM;-fo 1 30 3.39 1.53 –1.05 6.49 2.82 3.96
2 30 3.33 1.48 0.90 6.99 2.78 3.88
4 30 3.09 1.05 1.42 5.53 2.70 3.49
6 30 3.33 1.36 1.16 6.50 2.82 3.83
18 30 0.74 1.31 –2.22 2.85 0.26 1.23
HC 1.0% 1 30 0.37 1.03 –1.87 2.63 –0.02 0.75
2 30 0.24 0.93 –2.63 1.79 –0.11 0.58
4 30 –0.01 0.89 –2.85 1.43 –0.34 0.32
6 30 0.05 1.22 –3.44 2.40 –0.40 0.51
18 30 –0.08 0.82 –2.33 1.35 –0.38 0.23
BM 0.05% 1 30 3.26 1.52 1.12 7.23 2.70 3.83
2 30 3.31 1.73 1.04 6.94 2.67 3.96
4 30 2.98 1.36 0.70 6.23 2.47 3.49
6 30 3.36 1.49 1.06 6.46 2.81 3.92
18 30 0.76 1.25 –2.79 2.87 0.30 1.23
CP 0.05% 1 30 2.73 1.51 –0.09 5.76 2.16 3.29
2 30 2.77 1.66 –0.03 7.09 2.15 3.39
4 30 2.59 1.43 –0.14 5.59 2.06 3.12
6 30 3.07 1.51 0.09 5.73 2.51 3.63
18 30 0.81 1.13 –1.30 3.72 0.39 1.23
DM-o-V = DM-o vehicle; DM-fo-V = DM-fo vehicle; TP = time 
point; CL = confidence limits.
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 Discussion 
 The blanching activity of topical corticosteroids is a 
pharmacodynamic phenomenon which correlates well 
with clinical efficacy  [3, 6] . In this clinical study, the ac-
tivity of two DM formulations (DM-o and DM-fo) was 
compared with the activity of their active ingredient-free 
vehicles and the activity of three marketed active com-
parators of different strengths (HC 1.0%, BM 0.05%, and 
CP 0.05%). In this trial, a 6-hour open application for all 
study medications was chosen since this is an established 
treatment period for corticosteroids of medium potency 
such as DM. At baseline, the mean a * values were compa-
rable in all test fields, which confirms correct conditions 
for chromametric measurement and intraindividual 
comparison of different test fields. 
 One hour after the end of treatment, a clear reduction 
in the mean a * b * c * values was observed in the fields treat-
ed with DM-o, DM-fo, BM 0.05% and CP 0.05%. Only a 
slight reduction in the mean a * values was observed in the 
fields treated with the vehicles and HC 1.0%. The weak 
effect in the fields treated with HC 1.0% may be attrib-
uted to the study conditions optimized for the moderate-
potency glucocorticoids. 
 According to the classification of the strength of glu-
cocorticoids, it was expected that the highest degree of 
blanching would be seen in the fields treated with CP 
0.05% being the highest-potency corticosteroid. The 
ranking observed in this study can be explained by the 
importance of the vehicle composition and subsequent 
release of the corticosteroid from the vehicle. In this 
study, all of the vehicles of the study medications were 
different. It is likely that the release of CP from CP 0.05% 
was not as good as the release of the actives from the DM 
formulations and BM 0.05%. The role of the vehicle in the 
context of cutaneous bioavailability of topical corticoste-
roids is well established  [13] . In principle, vehicles of the 
ointment type, which are more fatty, may lead to better 
penetration of the active ingredient due to an occlusive 
effect and therefore to an amplification of the effect  [1, 
14] . As ointments are often considered favorable in the 
treatment of atopic dry skin, the DM formulations tested 
here look appropriate for initial treatment of manifest 
atopic eczema. 
 Conclusion 
 Topical bioavailability of DM was shown for both for-
mulations by chromametric measurement and clinical 
assessment in the vasoconstriction assay. DM-o, DM-fo 
and BM 0.05% showed a similar vasoconstrictive poten-
tial. CP 0.05% was found a little less active. HC 1.0% and 
the DM-o and DM-fo vehicles had no clear-cut vasocon-
strictive effect.
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